Kornimate/medical-research-clean huggingface dataset:
fat-induced release of glp-1 in humans

Conditions: Type 2 Diabetes

Summary: this study compared the incretin-releasing effect of c8-diet oil and tributyrin with that of 20 ml olive oil on a molar basis in human volunteers.

a structured triglyceride (1,3-di-octanoyl-2-oleoyl-glycerol, called c8-diet oil), which upon digestion results in generation of two medium-chain fatty acids and 2-oleoyl-glycerol (2-og), may lead to activation of gpr119 only, since medium fatty acids are poor agonists for fatty acid receptors.

Eligibility criteria:
inclusion criteria: * caucasian healthy male subjects * body mass index (bmi) 19 to 25 kg/m2 * informed consent exclusion criteria: * anaemia * diabetes mellitus * gastrointestinal diseases or operations interacting with intestinal absorption

Keywords: short fatty acids 2-oleoyl glycerol glp-1 secretion c8-diet oil gip secretion
plasma ctdna detection in diagnosis of epithelial ovarian cancer.

Conditions: Epithelial Ovarian Cancer

Summary: epithelial ovarian cancer constitutes one of the most common gynecological malignancies.because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctdna in cancer patients often bears similar genetic and epigenetic features to the related tumor dna.this study aims to detect plasma ctdna in diagnosis of epithelial ovarian cancer.

epithelial ovarian cancer constitutes one of the most common gynecological malignancies, with an incidence rate of 3-12/100 000 woman per year. because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage. liquid biopsy, which is meant to detect cancers by sequencing the dna in a few drops of a person's blood. it may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation. ctdna in cancer patients often bears similar genetic and epigenetic features to the related tumor dna. there is evidence that some of the ctdna originates from tumor tissue. this, and the fact that ctdna can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. this study aims to detect plasma ctdna in diagnosis of epithelial ovarian cancer.

Eligibility criteria:
inclusion criteria: * people aged 18years to 80years; * diagnosis of ovarian cancer is confirmed by two pathologists independently; * pregnancy tests are negative. exclusion criteria: * with other type of malignancies; * someone who refuse to participate the study.
recovering from bariatric surgery: the effects of early initiated and supervised mobilization

Conditions: Postoperative Pain, Acute; Postoperative Pain, Chronic; Bariatric Surgery; Mobilization; Physical Activity

Summary: the aim is to investigate the effect of early initiated and supervised mobilization continued after discharge as management of postoperative pain and recovery following obesity surgery, including patient experiences, pain coping, physical functionality and quality of life.

study aims; 1. to investigate the effect of mobilization as pain management following obesity surgery. 2. to investigate patient experiences with mobilization and postoperative pain, including the influence of mobilization on patients' ability to cope with pain and an identification of facilitating factors and barriers towards early mobilization. 3. to assess the effect of mobilization on postoperative recovery, including the general physical activity level, physical function, and quality of life among patients discharged after obesity surgery. the phd study consists of two sub-studies. study 1: effect of early mobilization as pain management in patients recovering from obesity surgery. the study is a single center randomized controlled trial (rct). participants will be randomized with an allocation ratio of 1:1. study 2: patient experiences with early mobilization and postoperative pain after surgery - an interview study patients participating in both interventions (group a), will be invited to participate in two individual semi structured interviews.

Eligibility criteria:
inclusion criteria: * the ability to read and understand the danish language exclusion criteria: * preoperative dependence of walking aids * vision impairment * previous syncopes or epilepsy * admission to the intensive care unit after surgery * acute complications during hospital admission * patients are excluded at baseline if they have an oxygen saturation below 90% or a systolic blood pressure above 180 mmhg

Keywords: pain coping bariatric surgery postoperative pain physical activity mobilization
evaluating efficacy and safety of oral melatonin in acute central serous chorioretinopathy

Conditions: Central Serous Chorioretinopathy; Melatonin; Ocular Diseases; Visual Acuity; Macula Abnormality

Summary: the goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (cscr) in adults. the main questions it aims to answer are: 1. how does melatonin affect central macula thickness in cscr? 2. how does melatonin affect visual acuity in cscr? researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat cscr. participants will: 1. take melatonin or placebo twice a day for one month 2. visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests 3. keep a diary of their symptoms


Eligibility criteria:
inclusion criteria: 1. patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks 2. patients with minimum age of 18 years old 3. consent to participate in the study exclusion criteria: 1. a history of vitrectomy 2. a history of laser surgery in the eye being studied in the past 3 months 3. a history of anti-vegf injection in the eye being studied in the past 3 months 4. history of patient suspicious for choroidal neovascularization (cnv) 5. pregnant or nursing patients 6. patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition 7. patients participating in any other investigational drug study 8. inability to obtain oct photographs
stress, inflammation and immune response pilot study- aim 3

Conditions: Systemic Lupus Erythematosus; Inflammation

Summary: the overall goal of this study is to investigate the effects of stress and glucose intake at the molecular level including gene expression, protein and functional analysis of immune cells in real time. aim 1- characterizing the immune response after acute stress and glucose consumption aim 2- temporal mapping of the modulation of immune cell function via meditation aim 3-influence of meditative practice on lupus patients aim 4-influence of meditative practice on healthy subjects current clinicaltrials.gov record, will be focused on aim-3 only. aim-3 will test whether meditation alters neutrophil function and inflammation in patients with lupus. study team will investigate whether patient neutrophils have altered net formation, phagocytosis, ros signaling and migration after abmp. innate immune function via analysis of monocytes by flow cytometry will also be analyzed. other immune cell responses including cd8 t cells will also be investigated.


Eligibility criteria:
inclusion criteria: * lupus diagnosis according to \>4 acr 1987 criteria or \>4 slicc 2012 criteria or a diagnosis confirmed by a board-certified rheumatologist * capacity to provide informed consent and ability to speak and read english * bmi under 35 * must have access to an ios or android smartphone to allow daily use of an app exclusion criteria: * currently participating in another clinical trial with intervention. participation in observational clinical trials is not grounds for exclusion. * history of significant systemic disease (eg. cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinological (diabetes), neurologic, rheumatologic, or gastrointestinal disease) * acute illness or evidence of clinically significant active infection * pregnant, breast feeding or less than 6 months post-partum * taking prescribed psychotropic or central nervous system altering medications * history of a diagnosed bipolar disorder, schizophrenia, or schizoaffective disorder, epilepsy or seizures * individuals who are currently undergoing a depressive episode. can include those who are under treatment and not depressed currently. * excluded based upon the screening visit * use of nicotine * significant previous training or significant current practice in meditation * completed mindfulness based stress reduction (mbsr) in the past * current meditation practice. judgment: participants will be included or excluded at the pis discretion due to wide variation in responses (e.g. 2 people answer yes, one practices mindfulness 2x/week for 2 years (exclude), the other attends regular religious services (include)) * significant daily practice with other mind-body techniques * daily yoga or tai chi practice - exclude * other daily practice - judgment

Keywords: neutrophil meditation
whole-body diffusion-weighted magnetic resonance imaging (mri) as a response biomarker for metastatic prostate cancer

Conditions: Prostate Cancer Metastatic

Summary: the skeleton is the most frequent organ of distal metastases in prostate cancer, often representing the only site of metastatic disease. still, assessment of response and progression to therapies in bone metastases remains a major unmet need, to aid treatment switch decisions, detecting primary/secondary resistance and to optimize drug development. the currently used standard imaging techniques, computed tomography (ct) and bone scintigraphy (bs), do not depict the true extent of bone metastases and are suboptimal in capturing biological changes occurring in response to treatment. this results in treatment switch decisions too often being based on psa changes, which is neither a surrogate of survival, nor an optimal response biomarker.diffusion-weighted imaging (dwi) is a functional magnetic resonance imaging (mri) technique that studies the movement of water molecules within a tissue and provides valuable information about the tissue microstructure and cellularity. whole body mri with dwi is highly accurate for bone metastases detection, outperforming the standard ct and bs and other imaging techniques when assessing bone metastases. the investigators hypothesise that dwi changes are a response biomarker in bone metastases from metastatic castration resistant prostate cancer (mcrpc); these dwi changes can be detected as early as after 4 weeks of systemic treatment.


Eligibility criteria:
inclusion criteria: * men 18 or over years old. * patients with castration resistant prostate cancer. * evidence of bone metastases by any imaging technique. * patients due to start treatment with abiraterone or enzalutamide. in the exploratory cohorts, we will include patients due to start treatment with other systemic therapies for advanced prostate cancer (a-taxanes, b-radiopharmaceuticals, c-other therapies). * written (signed and dated) informed consent. exclusion criteria: * contraindications to mri. * inability of patient to tolerate whole body mri (e.g. claustrophobia). * patients who have received radiotherapy within the last three months and with no bone metastases outside the radiotherapy field.

Keywords: response biomarker functional imaging mri
a study of orforglipron (ly3502970) in adult participants with obesity or overweight

Conditions: Obesity; Overweight

Summary: the main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. participation in the study will last approximately 8 months.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) * ≥30.0 kilograms per square meter (kg/m2), or * ≥27.0 kg/m2 with comorbidities exclusion criteria: * have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * have an unstable body weight within 90 days prior to screening * have acute or chronic hepatitis * are taking other medications or alternative remedies to manage weight loss

Keywords: visceral adipose tissue energy intake
the safety and immunogenicity evaluation of live attenuated influenza vaccine

Conditions: Influenza Prevention

Summary: live attenuated freeze-dried influenza vaccine has been licensed for use in 2020 (approval no.s20200002), the sponsor of this research submitted an new application for non freeze-dried live attenuated influenza vaccine in 2021. the main objective of phase two trail is to evaluate the immunogenicity of lavi (non freeze- dried). the secondary objective is to evaluate the safety of lavi (non freeze- dried).

totally 2520 health people aged 3-59 years old will be divided into two age group, containing 1260 in 18-59 years old and 1260 in 3-19 years old. all subjects will receive vaccination either lavi(non freeze- dried), lavi(freeze- dried) or placebo in a ratio of 2:2:1. all subjects will be collected any adverse events within 30 days and any serious adverse events within 6 months for safety evaluation. all subjects will be collected blood sample and nasopharyngeal swab for immunogenicity evaluation.

Eligibility criteria:
inclusion criteria: * healthy volunteers aged in 3-59 years old * had not received vaccination of influenza vaccine in the past one year * had not infected with influenza virus * this trail has been agreed by volunteers or his/her legal guardian * volunteers or his/her legal guardian will fellow this trail protocol exclusion criteria: * people with fever before vaccination, temperature higher than 37.0 # * females in suckling period, pregnancy (pregnancy test positive) or prepared to be pregnant * people given whole blood, plasma or immunoglobulin therapy within 3 months before vaccination * according to judgement of researchers, the subjects have any other factors that are not appropriate for this clinical trials * acute infectious disease or acute attack of chronic disease before inoculation * people get any vaccine within 14 days before the trial * people in immune deficiency or diagnosed with congenital or acquired immunodeficiency, people with immunosuppressive therapy in the past six months * people with epilepsy or a history of mental illness

Keywords: immunogenicity safety live attenuated influenza vaccine
effect of ea combined with ngf on limb function in convalescent patients with ischemic stroke

Conditions: Ischemic Stroke

Summary: most ischemic stroke patients are in recovery phase, often accompanied by motor impairment, but they lack effective treatment. the appearance of nerve growth factor (ngf) promotes the development of neuroprotective therapy, but it has little effect on stroke because of the blood-brain barrier (bbb). electroacupuncture (ea) has been used for stroke, while there is no significant clinical effect for recovery phrase. consequently, we will conduct a multicentre, randomised, controlled, assessor-blinded clinical trial to assess the effectiveness and safety of ea combined with ngf treatment on ischemic stroke recovery.


Eligibility criteria:
inclusion criteria: * people with first-ever ischemic stroke confirmed by ct or/and mri; * 14 days to 6 months after stroke onset; * 50 years≤aged≤80 years; * 3≤modified rankin score (mrs)≤4; * patients can accept treatment with ea and have good compliance; * patients have clear consciousness, pain perception and resolution ability to complete basic communication; * willing to participate and be randomized to one of the groups. exclusion criteria: * transient ischemic attack, subarachnoid hemorrhage, cerebral hemorrhage and other cerebrovascular diseases; * severe heart, liver, kidney dysfunction and severe coagulation dysfunction; cerebral infarction caused by repeated recurrence of stroke, brain surgery or trauma, and brain tumors; * severe neurological deficits before stroke, such as visual and auditory impairment, aphasia, agnosia, severe hemiplegia, or affected limb function before stroke, such as cerebral palsy, polio, fracture, and mrs≥1; * diseases with affecting cognitive function such as congenital dementia, or alcohol, drug or substance abuse ; * lactation, pregnancy or intend to be pregnant within 6 months; * needlesickness, needle phobia and skin infection at acupuncture site; * pacemaker, implantable cardioverter defibrillator carriers or conductive metallic foreign bodies in the body; * allergy to ngf; * currently enrolled in another clinical trial or participation in other clinical trials within the last 3 months.

Keywords: convalescence electroacupuncture nerve growth factor
double blind randomized clinical trial of use of colchicine added to standard treatment in hospitalized with covid-19

Conditions: COVID-19 Infection

Summary: ec coronacolchi is a multicenter, double-blind and randomized clinical trial with two branches. patients who meet all the inclusion criteria and none of the exclusion criteria will be randomized 1: 1 to be included in one of the following groups: * experimental group: colchicine for 2 weeks orally at the doses described, added to the standard treatment of covid-19. * control group: placebo for 2 weeks orally added to standard covid-19 treatment.


Eligibility criteria:
inclusion criteria: * 1 - acute symptoms compatible with sars-cov-2 infection: fever, cough, myalgia, dysgeusia / ageusia, dyspnea, pulmonary infiltrates on x-ray / ct, or any sign / symptom attributable to said infection * 2. microbiologically confirmed infection by sars-cov-2 (pcr and / or clia or elisa serology or with a valid microbiological diagnostic test with antigen test). * 3.\> 18 years. * 4. \<2 weeks from the onset of symptoms. * 5. admitted (with or without pneumonia) and ambulant (with pneumonia demonstrated by x-ray or ct) * 6. some analytical degree of moderate inflammation defined by pcr between 20 and 80 mg / l and / or ferritin between the high limit of normality (lan) and 3 times said lan * 7. signing of the informed consent, or acceptance of oral consent before witnesses. exclusion criteria: * 1. drug allergy. * 2. intolerance to lactose and / or cow's milk proteins. * 3. renal failure with gfr \<30 ml / min. * 4. liver cirrhosis or severe liver failure * 5. pregnancy or breastfeeding. * 6. blood dyscrasias or cardiac disorders that in the opinion of the investigator contraindicate the use of colchicine. * 7. pre-existing degenerative neuromuscular disease. * 8. acute or chronic diarrhea or malabsorptive syndrome that in the judgment of the clinician contraindicates the use of colchicine. * 9. crp\> 80 mg / l or ferritin\> 3 times lan * 10. shock or hemodynamic instability. * 11. respiratory distress measured by pao2 / fio2 \<300 or baseline o2 saturation ≤ 93%. * 12. patients undergoing mechanical ventilation. * 13. chronic treatment with any drug that, in the opinion of the investigator, interacts with colchicine and cannot be discontinued during the clinical trial, unacceptably increasing the risk of toxicity (digoxin, cyclosporine, etc.) * 14. have received any dose of colchicine, tocilizumab, any antil6 or antil1 drug. * 15. current treatment with corticosteroids (except chronic corticosteroid therapy without recent increase in dose). * 16. participation in any other clinical trial of patients with covid-19. * 17. any other condition that, in the opinion of the investigator, contraindicates the use of colchicine or puts the subject at risk due to their participation in the study.

Keywords: covid-19 colchicine
study to monitor the occurrence of viral variants in patients with compromised immune systems being treated for covid-19

Conditions: COVID-19

Summary: sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (sars-cov) and sars-cov-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization and/or death when administered as early treatment in non-hospitalized patients that are at risk for progression to severe disease. immunocompromised (ic) patients are prioritized to receive early treatment for covid-19 as they are at high risk of disease progression, and because of their potential for prolonged viral shedding and the resulting increased risk of emergent viral mutations and potential onward community transmission. this genomic surveillance study will aim to describe changes in the sars-cov-2 spike protein observed in ic participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.


Eligibility criteria:
inclusion criteria: * participants must be adult and of greater than or equal to (\>=) 18 years of age or older at the time of consent * participants must be immunocompromised (ic) population eligible to receive sotrovimab * a positive polymerase chain reaction (pcr) or antigen test for sars-cov-2 through clinical testing or routine screening undertaken as part of clinical management * prescribed treatment with sotrovimab as standard of clinical care * able to provide informed consent and willing to adhere to study-related procedures exclusion criteria: * participants who require hospitalization (related or not to covid-19) at baseline * participants who initiated sotrovimab therapy in inpatient settings * participants unable to perform nasal/oropharyngeal sample collection * blinded participants from other covid-19 related trials

Keywords: sars cov-2 lunar coronavirus disease 2019 (covid-19) pandemic sotrovimab monoclonal antibody immunocompromised (ic)
high intensity walking to reduce frailty

Conditions: Frailty

Summary: the purpose of this study is to evaluate a physical therapist (pt) led gait training intervention for 100 older adults with pre-frailty or frailty. the goals of this study are to determine the effect of gait training intensity on frailty, mobility, physical functioning, and quality of life, as well as balance and healthcare utilization.

frailty is a leading cause of dependency among older adults, affects up to 60% of older adults, and is associated with an increased risk for falls, hospitalizations, institutionalization, and death. exercise is the most widely recommended treatment for improving physical function among the frailty, but the optimal type or intensity of exercise is unknown. walking is a preferred physical activity among older adults, however, there are no clear guidelines on the best intensity of walking to reduce frailty. the specific goal of this project is to compare a high intensity walking (hiw) intervention (70-80% of heart rate maximum) to a moderate intensity walking (miw) intervention (50-60% of heart rate maximum) for pre-frail or frail older adults to determine the impact on frailty, mobility, balance, quality of life, and healthcare utilization.

Eligibility criteria:
inclusion criteria: * receiving services from cje seniorlife * pre-frailty or frailty as determined on the share-fi. * able to ambulate at least 10 feet with moderate assistance (\<50% physical assistance) or less. participants will be able to use their assistive device (e.g. cane or walker) during sessions. * \> 65 years of age * provision of informed consent and clearance for participation as determined by the exercise and screening for you (easy) exclusion criteria: * uncontrolled cardiovascular, metabolic, renal, or respiratory disease that limits exercise participation (e.g., previous heart attack within 3 months of enrollment or uncontrolled diabetes) * resting blood pressure \> 180/110 mmhg.59